The use and utility of toolkits in supporting cabotegravir plus rilpivirine long-acting implementation in the CARISEL (Cabotegravir And Rilpivirine Implementation Study in European Locations) study

被引：0
|
作者：
Trehan, Rekha [1 ]
Gutner, Cassidy [2 ]
Okoli, Chinyere [1 ]
Ghosn, Jade [3 ]
Vera, Francisco [4 ]
Florence, Eric [5 ]
Lutz, Thomas [6 ]
van der Valk, Marc [7 ,8 ]
Czarnogorski, Maggie [2 ]
机构：
[1] ViiV Healthcare, Brentford, England
[2] ViiV Healthcare, Durham, NC USA
[3] Univ Paris, Paris, France
[4] Hosp Gen Univ Santa Lucia, Murcia, Spain
[5] Inst Trop Geneeskunde, Antwerp, Belgium
[6] Infekt Res, Frankfurt, Germany
[7] Univ Amsterdam, Amsterdam, Netherlands
[8] Amsterdam Inst Infect & Immun, Amsterdam, Netherlands
来源：
HIV MEDICINE | 2023年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
P111
引用
收藏
页码：93 / 93
页数：1
相关论文
共 50 条
  • [31] Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
    Swindells, Susan
    Andrade-Villanueva, Jaime-Federico
    Richmond, Gary J.
    Rizzardini, Giuliano
    Baumgarten, Axel
    Masia, Mar
    Latiff, Gulam
    Pokrovsky, Vadim
    Bredeek, Fritz
    Smith, Graham
    Cahn, Pedro
    Kim, Yeon-Sook
    Ford, Susan L.
    Talarico, Christine L.
    Patel, Parul
    Chounta, Vasiliki
    Crauwels, Herta
    Parys, Wim
    Vanveggel, Simon
    Mrus, Joseph
    Huang, Jenny
    Harrington, Conn M.
    Hudson, Krischan J.
    Margolis, David A.
    Smith, Kimberly Y.
    Williams, Peter E.
    Spreen, William R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (12): : 1112 - 1123
  • [32] Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
    Daryl Hodge
    David J. Back
    Sara Gibbons
    Saye H. Khoo
    Catia Marzolini
    Clinical Pharmacokinetics, 2021, 60 : 835 - 853
  • [33] Question and answers on long-acting therapy with cabotegravir and rilpivirine in people with HIV
    Taramasso, Lucia
    Bonora, Stefano
    Cingolani, Antonella
    Di Biagio, Antonio
    Gianotti, Nicola
    Guaraldi, Giovanni
    Lo Caputo, Sergio
    Madeddu, Giordano
    Maggi, Paolo
    Marchetti, Giulia
    Nozza, Silvia
    Rusconi, Stefano
    Maggiolo, Franco
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2025, 80 (03) : 610 - 623
  • [34] A cautionary note on entry and exit strategies with long-acting cabotegravir and rilpivirine
    Ripamonti, Diego
    Rusconi, Stefano
    Zazzi, Maurizio
    AIDS, 2024, 38 (02) : 263 - 265
  • [35] Real world use of long-acting cabotegravir and rilpivirine in a HIV centre in Hong Kong
    Chan, M. C. J.
    Chik, S. H. T.
    Lamb, S. S.
    Choi, Y. C. C.
    Lau, W. T. A.
    Leung, C. S. E.
    To, P. Y. L.
    Lau, P. L. D.
    Tsang, T. Y. O.
    HIV MEDICINE, 2023, 24 : 155 - 156
  • [36] Long-acting cabotegravir/rilpivirine for HIV-1 treatment: real-world evaluation of barriers to implementation
    Wood, Brian R.
    Kassaye, Seble G.
    Gerstoft, Jan
    AIDS, 2023, 37 (04) : 689 - 691
  • [37] Long-acting cabotegravir plus rilpivirine as maintenance therapy: ATLAS week-48 results
    Margolis, D. A.
    Swindells, S.
    Andrade-Villanueva, J-F
    Richmond, G. J.
    Rizzardini, G.
    Baumgarten, A.
    Masia, M. D. M.
    Latiff, G.
    Pokrovsky, V.
    Mrus, J. M.
    Huang, J. O.
    Hudson, K. J.
    Smith, K. Y.
    Williams, P.
    Spreen, W. R.
    HIV MEDICINE, 2019, 20 : 20 - 21
  • [38] An evaluation of long-acting cabotegravir plus rilpivirine for the treatment of virologically suppressed adults living with HIV
    Qazzaz, Hamdi
    Parganas, Christopher
    Cory, Theodore James
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (13) : 1485 - 1495
  • [39] Top practices for implementing cabotegravir (CAB) and rilpivirine (RPV) long-acting (LA) in European clinics
    Olalla, Julian
    Gutner, Cassidy
    Pascual-Bernaldez, Miguel
    Hernandez, Beatriz
    Dakhia, Samia
    Slama, Laurence
    Crusells Canales, Maria Jose
    Lutz, Thomas
    van der Valk, Mark
    van Welzen, Berend
    Florence, Eric
    Barnes, Nicola
    Cooper, Owen
    Filipenko, Dina
    Czarnogorski, Maggie
    HIV MEDICINE, 2022, 23 : 27 - 28
  • [40] COST-EFFECTIVENESS OF LONG-ACTING CABOTEGRAVIR PLUS LONG-ACTING RILPIVIRINE FOR THE TREATMENT OF HIV-1 IN TAIWAN
    Wen, Y. C.
    Ou, H. T.
    Tien, K.
    Harrison, C.
    Omonmhenle, D.
    Turner, M.
    Anderson, S. J.
    Jacob, I
    VALUE IN HEALTH, 2023, 26 (06) : S145 - S145
12345